Semaglutide and tirzepatide reduce alcohol consumption in people with obesity: Real-world evidence
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Studies suggest a role for brain-derived GLP-1 in the control of eating and reward (80, 81), but there is no evidence that peripherally administered GLP-1RAs can directly access GLP-1Rs in these regions, as demonstrated by the lack of fluorescently labeled semaglutide in these brain nuclei
Avoid lying flat on your back
Bowel mucosa, and integrity of the intestinal epithelial barrier, is protected by IL-17, 57 meaning its removal will eventually disrupt this barrier leading to further penetration of bacteria and worsening of inflammation
Seek urgent medical attention if you cannot keep fluids down for more than 24 hours, experience severe persistent abdominal pain radiating to your back, develop signs of dehydration (reduced urine output, dizziness when standing), or notice symptoms of gallbladder disease such as right upper quadrant pain with fever or jaundice